Outlook Therapeutics OTLK
NASDAQ OTLK
$0.65 -0.03 (-4.30%)
As of: Aug 21, 2026 · 3:59 PM EDT

Outlook Therapeutics (OTLK) Return on Sales (2015 - 2025)

Outlook Therapeutics (OTLK) posted quarterly Return on Sales of 1.45% for Q3 2025, up 1181.54% quarter-over-quarter from 0.13% in Q2 2025.

Outlook Therapeutics (OTLK) Return on Sales (2015 - 2025) Analysis & Trends

Outlook Therapeutics (OTLK) has reported Return on Sales for 6 consecutive years, with 1.45% the latest figure, recorded in Q3 2025.

  • In Q3 2025, Return on Sales changed N/A year-over-year to 1.45%; the TTM figure through Sep 2025 stood at 0.13% (changed N/A YoY), while the FY2025 annual figure was 0.44%, changed N/A from the prior year.
  • Return on Sales grew to 1.45% in Q3 2025 per OTLK's latest filing, from 0.13% in the prior quarter.
  • Across five years, Return on Sales topped out at 1.45% in Q3 2025 and bottomed at 0.13% in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 0.00%
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 0.00%
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 0.00%
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -0.05%
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 0.00%
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 0.00%
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 0.00%
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 0.00%
9 Royalty Pharma 27.27 Bn 26.43 Bn - 0.00%
10 Outlook Therapeutics 88.50 Mn 77.26 Mn -8,265.00 -

Historic Data

Download Data
DateValue
Sep 30, 2025 1.45%
Jun 30, 2025 -0.13%
Sep 30, 2019 -0.02%
Jun 30, 2019 -0.08%
Mar 31, 2019 -0.16%
Dec 31, 2018 -0.09%
Sep 30, 2018 -0.16%
Jun 30, 2018 -0.11%
Mar 31, 2018 -0.10%
Dec 31, 2017 -0.02%
Sep 30, 2017 -0.02%
Jun 30, 2017 -0.18%
Mar 31, 2017 -0.27%
Dec 31, 2016 -0.63%
Sep 30, 2016 -0.21%
Jun 30, 2016 -0.45%
Mar 31, 2016 -0.04%
Dec 31, 2015 -0.17%
Sep 30, 2015 -0.36%
Jun 30, 2015 -0.09%